Under 10% of people who could benefit from weight-loss injections such as Wegovy can access them, caution the World Health Organization as it releases its initial advice on the drugs.
With over a billion individuals worldwide now obese, it is advocating for more widespread and fairer access to GLP-1 medication.
Per forecasts, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.
"Our latest guidelines recognises that excess weight is a chronic disease that can be managed with holistic and ongoing treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and logistical bottlenecks are significant obstacles to widespread access to the injections that can assist patients in reducing substantial weight, says the agency.
Despite the present best projected outlook, the production of GLP-1 therapies would only suffice for approximately 100 million people – under 10% of the global need, per the WHO.
The recommendation urges governments and firms to expand availability, through strategies including licensing agreements.
The intellectual property rights on semaglutide – the main ingredient of the drug Wegovy – is scheduled to end in several countries in 2026.
The injections replicate a biological compound to slow digestion, curb appetite and increase satiety so users reduce food intake.
Individuals usually see weight reduction within a few weeks of commencing the once-weekly jabs.
Studies indicates people may see weight return after a year of discontinuing the drug, as their typical appetite return.
To be above a healthy weight increases your chance for experiencing health problems, such as type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies.
Excess weight impacts individuals in countries worldwide and was associated with millions of deaths worldwide in 2024, per the health agency.
A seasoned gaming analyst with over a decade of experience in casino strategy and game development.
Chad Watts
Chad Watts